Cargando…
Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?
BACKGROUND: In daily clinical setting, some patients affected by relapsing-remitting Multiple Sclerosis (RRMS) are switched from the low-dose to the high-dose Interferon beta (IFNB) in order to achieve a better control of the disease. PURPOSE: In this observational, post-marketing study we reported...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3058026/ https://www.ncbi.nlm.nih.gov/pubmed/21352517 http://dx.doi.org/10.1186/1471-2377-11-26 |